Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NNMT | P40261 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1091883 | 0.83 | NNMT (0.45) | KDM4EL3MBTL1LMNANNMTALDH1A1 | |
| SCHEMBL31670741 | 0.83 | MAPT (0.49) | L3MBTL1LMNARAB9ACA12CA1 | |
| SCHEMBL24774417 | 0.81 | MAPT (0.57) | L3MBTL1NNMTGABRA5ALDH1A1MAPT | |
| SCHEMBL22924506 | 0.81 | GRM5 (0.49) | GABRA5 | |
| SCHEMBL28093725 | 0.81 | MAPK1 (0.53) | MAPK1KDM4EL3MBTL1LMNANNMT | |
| SCHEMBL65277 | 0.81 | NNMT (0.68) | MAPK1KDM4EL3MBTL1LMNANNMT | |
| SCHEMBL2431102 | 0.81 | MAPK1 (0.46) | MAPK1KDM4EL3MBTL1LMNANNMT | |
| SCHEMBL21669621 | 0.80 | NNMT (0.62) | KDM4EL3MBTL1NNMTMAPT | |
| SCHEMBL27812352 | 0.79 | MAPT (0.47) | KDM4EL3MBTL1NNMTRAB9ATDP1 | |
| SCHEMBL24774416 | 0.79 | MLYCD (0.43) | KDM4EL3MBTL1NNMTGABRA5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279227-A1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN BIOTECH, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-117881661-A | Condensed heterocyclic derivative | 杨森科学爱尔兰无限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-11952364-B2 | TRK inhibitors useful as anticancer drugs | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2024-04-09 | — | — | US | disclosed |
| CN-112739691-B | TRK inhibitors as anticancer agents | 泰励生物科技（上海）有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2022253255-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
| US-20220388983-A1 | TRK INHIBITORS USEFUL AS ANTICANCER DRUGS | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2022-12-08 | — | — | US | disclosed |
| CN-108463458-B | Modulators of ROR-gamma | 生命医药有限责任公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3848365-A1 | TRK INHIBITOR AS ANTI-CANCER DRUG | Tyligand Bioscience (Shanghai) Limited (CN) | 2021-07-14 | — | — | EP | disclosed |
| US-11008340-B2 | Modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3377482-B1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2021-05-12 | — | — | EP | disclosed |
| EP-3377482-B1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2021-05-12 | — | — | EP | disclosed |
| CN-112739691-A | TRK inhibitors as anticancer agents | 泰励生物科技（上海）有限公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20190322687-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC (US) | 2019-10-24 | — | — | US | disclosed |
| EP-3377482-A1 | MODULATORS OF ROR-GAMMA | Vitae Pharmaceuticals, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
| CN-108463458-A | MODULATORS OF ROR-GAMMA | 生命医药公司 | 2018-08-28 | — | — | CN | disclosed |
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | disclosed |
| EP-2638008-B1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-01 | — | — | EP | disclosed |
| EP-2638008-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | disclosed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008340-B2 | Modulators of ROR-gamma | RORC, RORB, RORA | MAPK1 1515/4885KDM4E 3166/4885L3MBTL1 4612/4885 |
| US-20190322687-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | MAPK1 1515/4885KDM4E 3166/4885L3MBTL1 4612/4885 |
| US-11952364-B2 | TRK inhibitors useful as anticancer drugs | NTRK1, NTRK3, MUSK | MAPK1 304/4885KDM4E 2651/4885L3MBTL1 1715/4885 |
| US-20220388983-A1 | TRK INHIBITORS USEFUL AS ANTICANCER DRUGS | NTRK1, NTRK3, MUSK | MAPK1 304/4885KDM4E 2651/4885L3MBTL1 1715/4885 |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | MAPK1 3955/4885KDM4E 2065/4885L3MBTL1 4737/4885 |
| US-20240279227-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | MAPK1 4056/4885KDM4E 3515/4885L3MBTL1 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.